Primary Myelofibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data suggest that PMF monocytes induce myelofibrosis-like phenotype in immunodeficient mice and that PMF and normal BM-derived CD14+/CD34- monocytes give rise to megakaryocyte progenitor cells.
|
31569199 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recently described the upregulation of MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) in PMF CD34+ hematopoietic progenitor cells (HPCs) compared to healthy donor.
|
28745329 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since we recently uncovered the upregulation of miR-34a-5p in PMF CD34+ hematopoietic progenitor cells (HPCs), in order to elucidate its role in PMF pathogenesis here we unravelled the effects of miR-34a-5p overexpression in HPCs.
|
28098757 |
2017 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, high LGALS1 expression was found in CD34(+) cells but not in leucocytes from patients with PMF, in absence of JAK2 V617F mutation, and also in SET-2 cells treated with JAK inhibitor.
|
27402956 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, LCP4 treatment resulted in the depletion of the number of MF HPCs that were JAK2V617F(+) Moreover, the degree of human cell chimerism and the proportion of malignant donor cells were significantly reduced in immunodeficient mice transplanted with MF CD34(+) cell grafts treated with LCP4.
|
27114459 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that a number of CD34+ <10/μl excludes the diagnosis of primary myelofibrosis with a sensitivity of 97 % and a specificity of 90 % (area under the curve: 0.93 [0.89-0.98]; p < 0.001).
|
27582015 |
2016 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicate that the MF splenic microenvironment is characterized by increased levels of intact, functional CXCL12, which contributes to the localization of MF CD34(+) cells to the spleen and the establishment of extramedullary hematopoiesis.
|
25461253 |
2015 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A histone deacetylase inhibitor, panobinostat, significantly increased MIRLET7 expression and reduced variant 1 of HMGA2 mRNA expression, but not variant 2, in both U937 cells and PMF-derived CD34(+) cells.
|
25236537 |
2015 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the effect of the drug on MF stem cells (MF-SCs), splenic CD34(+) cells were treated with AZD1480 and transplanted into immunodeficient mice.
|
25193869 |
2014 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because the validation of miRNA-target interactions unveiled JARID2/miR-155-5p as the strongest relationship in the network, we studied the function of this axis in normal and PMF CD34(+) cells.
|
25097177 |
2014 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of polycythemia vera (PV) and primary myelofibrosis (PMF) CD34(+) cells with low doses of RG7112 and Peg-IFNα 2a before their transplantation into immune-deficient mice decreased the degree of donor-derived chimerism as well as the JAK2V617F allele burden, indicating that these drugs can each alone or in combination deplete MPN HSCs.
|
24869939 |
2014 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that treatment with the dual phosphoinositide-3-kinase (PI3K)/AKT and mTOR inhibitor BEZ235 attenuated PI3K/AKT and mTOR signaling, as well as induced cell-cycle growth arrest and apoptosis of the cultured human JAK2-V617F-expressing HEL92.1.7 (HEL), UKE1 cells, and primary CD34+ myelofibrosis (MF)-MPN cells.
|
23445613 |
2013 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we evaluated the apoptosis-related gene and protein expression of BCL2 family members in bone marrow CD34+ hematopoietic stem cells (HSC) and peripheral blood leukocytes from ET and PMF patients.
|
22300941 |
2012 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two to 6 months after the transplantation of CMAs treated JAK2V617F(+) PMF CD34(+) cells into nonobese diabetic/severe combined immunodeficient (SCID)/IL-2Rγ(null) mice, the percentage of JAK2V617F/JAK2(total) in human CD45(+) marrow cells was dramatically reduced.
|
20858855 |
2010 |
Primary Myelofibrosis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These data point to abnormal methylation of the CXCR4 promoter as a mechanism contributing to constitutive migration of CD34(+) cells in PMF.
|
18511598 |
2008 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, a marked augmentation in HR activity was found in CD34(+)-derived cells isolated from patients with polycythemia vera or primitive myelofibrosis compared with control samples.
|
18515659 |
2008 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CD34(+) cell JAK2(V617F) clonal dominance, defined as coherence between the CD34(+) cell and neutrophil JAK2(V617F) allele burdens, was present in 24% of ET, 56% of PV, and 93% of PMF patients, and was independent of the CD34(+) cell JAK2(V617F) genotype.
|
18723264 |
2008 |
Primary Myelofibrosis
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
These data point to abnormal methylation of the CXCR4 promoter as a mechanism contributing to constitutive migration of CD34(+) cells in PMF.
|
18511598 |
2008 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone marrow cellularity values and the numbers of CD34+ and CD117+ blasts in the ET and CIMF groups did not differ.
|
17875526 |
2007 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, molecular profiling of IM CD34(+) cells uncovered a limited number of genes with altered expression that, beyond their putative role in disease pathogenesis, are associated with patients' clinical characteristics and may have potential prognostic application.
|
16990584 |
2007 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The enumeration of CD34-positive cells in the peripheral blood and the presence of circulating endothelial progenitor cells are the new important ancillary tests for the diagnosis of a small subset of patients with CIMF with atypical presentation.
|
16879014 |
2006 |
Primary Myelofibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The predictive power of these genes was verified by applying the algorithm to an unknown test set containing expression data from eight additional CD34+ samples (four AMM, four control).
|
15849170 |
2005 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Idiopathic myelofibrosis (IM) is characterized by the constitutive mobilization of CD34(+) cells.
|
15471948 |
2005 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The myeloproliferation is characterized by an increased number of circulating CD34+ progenitors with the prominent amplification of dystrophic megakaryocytic (MK) cells and myeloid metaplasia in the spleen and liver.
|
15454487 |
2005 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a variant form, French-American-British (FAB) M3v, of acute promyelocytic leukemia (APL; FAB M3) with atypical morphocytochemical features, immature antigens (CD34 and HLA-DR) and marked myelofibrosis (MF).
|
11721970 |
2001 |